32 research outputs found
Etude clinique de patients présentant une fixation indirecte monotypique en immunofluorescence
ANGERS-BU MĂ©decine-Pharmacie (490072105) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Perioperative Considerations in Transoral Robotic Surgery (TORS): Experience of CHU UCL Namur
Transoral Robotic Surgery (TORS) is an emerging technique for the treatment of head and neck tumors. The aim of this paper is to describe our experience of perioperative considerations. Indeed, TORS is feasible, safe, and both oncologically and functionally effective. However, this technology has certain perioperative implications. We present the experience of anesthesiologists and surgeons over the past ten years with the Da Vinci Surgical System, and strongly recommend assigning a specific medical and paramedical team to shorten the learning curve and manage this innovative surgical technique with confidence and expertise
Effectiveness of the South African Program of Immunization against Hepatitis B in Children Infected with Human Immunodeficiency Virus-1 living in a resource-limited setting of Kwazulu-Natal.
This survey showed low rates of HBV chronic infection in HIV-infected and uninfected children living in a RLS of KZN province. The vertical and horizontal transmissions before 5 years of age decreased in both cohorts since the introduction of the HBV vaccine. Due to their weaker immune system, HIV-infected children had lower anti-HBs rates than the HIV-uninfected patients. Without establishing regular monitoring of their immunity and adaptation of the vaccine schedule, prevalence of HBV could stay high in SA despite optimal vaccination coverage in HIV-infected patients. 1.World Health Organization, 2014. HIV/AIDS (Accessed January 2016). http://www.who.int/hiv/en/ 2.Phung BC, Sogni P, Launay O. 2014 Hepatitis B and human immunodeficiency virus co-infection. World J Gastroenterol. 14;20(46):17360-7. 3.Healy SA, Gupta S, Melvin AJ. 2013. HIV/HBV coinfection in children and antiviral therapy. Expert Rev Anti Infect Ther. 11(3):251-63. 4.Amponsah-Dacosta E, Lebelo RL, Rakgole JN, Burnett RJ, Selabe SG, Mphahlele MJ. 2014. Evidence for a change in the epidemiology of hepatitis B virus infection after nearly two decades of universal hepatitis B vaccination in South Africa. J Med Virol. 86(6):918-24. 5.Simani OE, Leroux-Roels G, François G, Burnett RJ, Meheus A, Mphahlele MJ. 2009. Reduced detection and levels of protective antibodies to hepatitis B vaccine in under 2-year-old HIV positive South African children at a paediatric outpatient clinic. Vaccine. 1;27(1):146-51
Conservative management of pneumatosis intestinalis following haematopietic stem cell transplantation for major beta thalassemia
Sleep and cardiorespiratory characteristics of infant victims of sudden death: A prospective case-control study
SCOPUS: ar.jinfo:eu-repo/semantics/publishe
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: Effect of response quality on survival - A study from the groupe d'etude des lymphomes de l'adulte
Purpose: First-line treatment for patients with newly diagnosed follicular lymphoma (FL) still remains debated, even in the rituximab-based combination therapy era. Few studies have addressed the question whether complete remission (CR) translates into better survival. The aim of this study was to assess the long-term follow-up of prospectively treated patients with FL and the potential correlation between response quality to first-line treatment and overall survival (OS). Patients and Methods: Data from 536 patients with FL with low (n = 193) or high (n = 343) tumor burden enrolled from October 1986 to May 1995 in the French and Belgian GELF86 studies were analyzed. Data from these trials have been previously reported for low-tumor burden and high-tumor burden patients. Results: Median follow-up was 14.9 years, and median OS was 9.8 years. Treated patients who achieved a complete response (CR; n = 194; 45%) had a significant longer OS than those only reaching a partial response (PR; n = 168; 39%) throughout treatment (hazard ratio [HR], 0.55; 95% CI, 0.42 to 0.72; P < .001) in an univariate time-dependent Cox model. Similar findings were found when response to treatment (CR v PR) was adjusted for potentially confounding factors in a multivariate model (HR, 0.53; 95% CI, 0.38 to 0.73; P < .001). Conclusion: These data provide a long follow-up of these patients' cohorts and indicate that a better response to first-line treatment translates into an improved survival for patients with FL. Therefore, response-adapted therapy aiming to achieve a CR should be considered as first-line treatment. © 2009 by American Society of Clinical Oncology